Association of Oxidative Stress Markers with Vascular Stiffness Parameters in Patients with Diabetic Neuropathy

Introduction: One of the most common chronic complications of diabetes mellitus is diabetic neuropathy. The aim of the study was to elucidate the association between selected markers of oxidative stress and markers of vascular stiffness and to contribute to the understanding of the pathophysiological links between oxidative stress and micro- and macrovascular complications of diabetes. Methods: We enrolled patients with type 2 DM (n = 49), with moderate to severe diabetic polyneuropathy of lower extremities, and a control group without microvascular complications (n = 29). The neuropathy group received alpha-lipoic acid infusion therapy. Sampling was performed before and after treatment to determine the level of oxidative markers (advanced glycation end-products—AGEs, glycation products of AOPP proteins, MDA malondialdehyde and oxidized LDL), parameters of metabolic control and parameters of vascular wall stiffness were measured by sphygmomanometry. Results: After the administration of alpha-lipoic acid, we demonstrated a significant reduction in the level of three selected oxidation markers (AOPP: p < 0.001, AGE: p < 0.001, oxLDL: p < 0.05). In contrast, the level of MDA did not change significantly (p = 0.83). Throughout the group, oxLDL was significantly correlated with central BP (SBP and DBP in the aorta, p < 0.05 and <0.01) and with the augmentation index (AiX/75 bpm, p < 0.01). AOPP significantly correlated with systolic BP in the aorta (p < 0.05). We did not find significant associations in the remaining oxidation markers. Conclusion: In our study, we demonstrated a reduction in the level of oxidative markers after alpha-lipoic acid administration and also an association between markers of oxidative damage to lipids and proteins (oxLDL and AOPP) and some parameters of vascular stiffness.

Download Full-text

Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis

Life Sciences ◽

10.1016/j.lfs.2018.10.055 ◽

2019 ◽

Vol 216 ◽

pp. 101-110 ◽

Cited By ~ 10

Author(s):

Nasrin Sadeghiyan Galeshkalami ◽

Mohammad Abdollahi ◽

Rezvan Najafi ◽

Maryam Baeeri ◽

Akram Jamshidzade ◽

...

Keyword(s):

Oxidative Stress ◽

Diabetic Neuropathy ◽

Lipoic Acid ◽

Coenzyme Q10 ◽

Alpha Lipoic Acid ◽

Experimental Diabetic Neuropathy

Download Full-text

Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy

Diabetes ◽

10.2337/diabetes.49.6.1006 ◽

2000 ◽

Vol 49 (6) ◽

pp. 1006-1015 ◽

Cited By ~ 241

Author(s):

M. J. Stevens ◽

I. Obrosova ◽

X. Cao ◽

C. Van Huysen ◽

D. A. Greene

Keyword(s):

Oxidative Stress ◽

Blood Flow ◽

Energy Metabolism ◽

Diabetic Neuropathy ◽

Peripheral Nerve ◽

Lipoic Acid ◽

Alpha Lipoic Acid ◽

Flow Energy ◽

Experimental Diabetic Neuropathy ◽

And Oxidative Stress

Download Full-text

Alpha Lipoic Acid Influence in the Attenuation of Oxidative Stress and of Clinical Manifestations of Neuropathy in Diabetes Mellitus Patients

Internal Medicine ◽

10.2478/inmed-2018-0026 ◽

2018 ◽

Vol 15 (4) ◽

pp. 15-26

Author(s):

Bondar Andrei Cristian ◽

Popa Amorin Remus

Keyword(s):

Oxidative Stress ◽

Diabetes Mellitus ◽

Diabetic Neuropathy ◽

Lipoic Acid ◽

Healthy Subjects ◽

Microvascular Complications ◽

Clinical Manifestations ◽

Clinical Aspects ◽

Alpha Lipoic Acid ◽

Perception Threshold

AbstractAlpha lipoic acid is an antioxidant substance used for the pathogenic treatment of diabetic neuropathy, oxidative stress being a central mechanism in diabetic microvascular complications. Our study included 24 diabetes mellitus patients with diabetic neuropathy and 20 healthy subjects. Diabetes patients were given alpha lipoic acid 600 mg intravenously for 10 days and then per os for 30 days.Significant improvements were observed concerning oxidative stress evaluated by measuring serum malondyaldehide and ceruloplasmin. The clinical characteristic of neuropathy improved, both the level of pain decreased and the vibration perception threshold increased. Our study demonstrated a two times higher level of oxidative stress in patients with diabetes compared to healthy subjects, and that by influencing oxidative stress we could influence the clinical aspects of neuropathy. Further investigations need to be done to explore the pleiotropic effects of alpha lipoic acid on other mechanisms that are implicated in the pathogenies of diabetic neuropathy.

Download Full-text

Changes of oxidative stress markers after treatment of diabetic neuropathy with alpha-lipoic acid

Atherosclerosis ◽

10.1016/j.atherosclerosis.2018.06.634 ◽

2018 ◽

Vol 275 ◽

pp. e204-e205

Author(s):

F.S. Ferenc sztanek ◽

Hajnalka Lorincz ◽

Dora Banyai ◽

Petra Sandor ◽

Agnes Molnar ◽

...

Keyword(s):

Oxidative Stress ◽

Diabetic Neuropathy ◽

Lipoic Acid ◽

Alpha Lipoic Acid ◽

Oxidative Stress Markers ◽

Stress Markers

Download Full-text

The Effect of 600 mg Alpha-lipoic Acid Supplementation on Oxidative Stress, Inflammation, and RAGE in Older Adults with Type 2 Diabetes Mellitus

Oxidative Medicine and Cellular Longevity ◽

10.1155/2019/3276958 ◽

2019 ◽

Vol 2019 ◽

pp. 1-12 ◽

Cited By ~ 13

Author(s):

Víctor Manuel Mendoza-Núñez ◽

Beatriz Isabel García-Martínez ◽

Juana Rosado-Pérez ◽

Edelmiro Santiago-Osorio ◽

José Pedraza-Chaverri ◽

...

Keyword(s):

Oxidative Stress ◽

Diabetes Mellitus ◽

Older Adults ◽

Lipoic Acid ◽

Glycosylated Hemoglobin ◽

Total Antioxidant Status ◽

Control Group ◽

Alpha Lipoic Acid ◽

Markers Of Inflammation

Alpha-lipoic acid (ALA) has been used as a dietary supplement at different doses in patients with diabetes mellitus type 2 (T2DM) due to its antioxidant, anti-inflammatory, and hypoglycemic effects. However, the reports on the effects of ALA are controversial. For this reason, the purpose of the present study was to determine the effect of 600 mg/day of ALA on the markers of oxidative stress (OxS) and inflammation and RAGE in older adults with T2DM. A quasiexperimental study was carried out with a sample of 135 sedentary subjects (98 women and 37 men) with a mean age of64±1years, who all had T2DM. The sample was divided into three groups: (i) experimental group (EG) with 50 subjects, (ii) placebo group (PG) with 50 subjects, and control group (CG) with 35 subjects. We obtained the following measurements in all subjects (pre- and posttreatment): glycosylated hemoglobin (HbA1c), receptor for advanced glycation end products (RAGE), 8-isoprostane, superoxide dismutase (SOD), glutathione peroxidase (GPx), total antioxidant status (TAS), and inflammatory (CRP, TNF-α, IL-6, IL-8, and IL-10) markers. Regarding the effect of ALA on HbA1c, a decrease was observed in the EG (baseline8.9±0.2vs. posttreatment8.6±0.3) and the PG (baseline8.8±0.2vs. posttreatment8.4±0.3) compared to the CG (baseline8.8±0.3vs. six months9.1±0.3) although the difference was not statistically significant (p<0.05). There was a statistically significant decrease (p<0.05) in the blood concentration of 8-isoprostane in the EG and PG with respect to the CG (EG: baseline100±3vs. posttreatment57±3, PG: baseline106±7vs. posttreatment77±5, and CG: baseline94±10vs. six months107±11pg/mL). Likewise, a statistically significant decrease (p<0.05) in the concentration of the RAGE was found in the EG (baseline1636±88vs. posttreatment1144±68) and the PG (baseline1506±97vs. posttreatment1016±82) compared to CG (baseline1407±112vs. six months1506±128). A statistically significant decrease was also observed in all markers of inflammation and in the activity of SOD and GPx in the CG with respect to the EG and PG. Our findings suggest that the administration of ALA at a dose of 600 mg/day for six months has a similar effect to that of placebo on oxidative stress, inflammation, and RAGE in older adults with T2DM. Therefore, higher doses of ALA should be tried to have this effect. This trial is registered with trial registration numberISRCTN13159380.

Download Full-text

Neurophysiological evaluation of short-term outcome of pharmacological treatment of diabetic neuropathy

Vojnosanitetski pregled ◽

10.2298/vsp151209261c ◽

2017 ◽

Vol 74 (8) ◽

pp. 723-727 ◽

Cited By ~ 1

Author(s):

Milan Cvijanovic ◽

Svetlana Simic ◽

Aleksandar Kopitovic ◽

Ranko Raicevic

Keyword(s):

Diabetic Neuropathy ◽

Conduction Velocity ◽

Lipoic Acid ◽

Diabetic Polyneuropathy ◽

Control Group ◽

Alpha Lipoic Acid ◽

Electrophysiological Monitoring ◽

Sensory Conduction ◽

Neuroprotective Therapy ◽

F Wave

Background/Aim. Diabetic polyneuropathy (DPN) is a very frequent and progressive disease that severely impairs the overall quality of life, accompanied by a high rate of disability. For these reasons, the testing of therapeutic agents for this disease is increasing. Methods. We tested the most frequently used drugs for diabetic neuropathy in our area, along with electrophysiological monitoring in order to avoid subjectivity and the "placebo effect". A total of 120 patients were divided into four groups: three groups who received alpha-lipoic acid, benfotiamine or gabapentin respectively, and the control group who did not receive any treatment. In all the patients we analyzed motor conduction velocity, distal latency, sensory conduction velocity, F wave and F wave chronodispersion before and after treatment with each drug. Results. It is evident that some drugs had a favorable impact on the condition of the peripheral nerves. Alpha-lipoic acid and benfotiamine had an impact on the recovery of the nerve, i.e. pathophysiological processes, whereas gabapentin had no impact on the recovery, similarly to the control group without any treatment. Electrophysiological indicators had different sensitivity to detect conditions of the peripheral neurons. The best effect, in terms of increased sensory conduction velocity, had the patients treated with alpha-lipoic acid. Conclusion. The effect of alpha-lipoic acid and benfotiamine on the condition of peripheral nerve was evident. The failure of recovery, i.e. deterioration of electrophysiological parameters in patients who did not receive neuroprotective therapy suggests the need of permanent medication and periodic electrophysiological monitoring of patients with diabetic polyneuropathy.

Download Full-text

Antioxidants Supplementation In Acute Amitriptyline Abuse for Pain

10.21203/rs.3.rs-724699/v1 ◽

2021 ◽

Author(s):

Hameed Kadar Ali S ◽

Wasim Ali Raja K ◽

IRFAN Navabshan ◽

Mohammad Habeeb ◽

Ismail Y

Keyword(s):

Oxidative Stress ◽

Vitamin C ◽

Lipoic Acid ◽

Standard Treatment ◽

Human Subjects ◽

Control Group ◽

P Value ◽

Alpha Lipoic Acid ◽

Group V ◽

Group I

Abstract The fundamental aim of this study is to establish the role of anti-oxidant supplementation in alleviating acute amitriptyline induced oxidative stress. The effect of supplementation was compared on treatment of acute amitriptyline intoxication cases for pain management, with Alpha lipoic acid (ALA) alone or with vitamin C, with that of healthy individuals (Group I), and those receiving only routine standard treatment (RST) as control (Group II). Total of 132 human subjects divided into 5 groups were supplemented with either placebo, RST, RST with Vitamin C, RST with ALA, or RST with Vitamin C and ALA. Results of this study revealed that the decrease in the level of oxidative stress and enzyme activity was observed among those supplemented with either Alpha lipoic acid alone or along with vitamin C, with a slightly more decrease in the latter group. P value < 0.001 was considered statistically significant. The percentage of benefit of treatment on supplementation with vitamin C and Alpha lipoic acid showed a marked increase in-group V cases after supplementation with both in combination. The results provided that the oxidative stress induced by acute amitriptyline poisoning is comparatively decreased by supplementation with antioxidants like Alpha lipoic acid and Vitamin C, than those only on routine standard treatment.

Download Full-text

Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with diabetic neuropathy

Atherosclerosis ◽

10.1016/j.atherosclerosis.2017.06.852 ◽

2017 ◽

Vol 263 ◽

pp. e263 ◽

Cited By ~ 1

Author(s):

Ferenc Sztanek ◽

Ildiko Seres ◽

Hajnalka Lorincz ◽

Agnes Molnar ◽

Gyorgy Paragh

Keyword(s):

Oxidative Stress ◽

Diabetic Neuropathy ◽

Lipoic Acid ◽

Antioxidative Defense ◽

Alpha Lipoic Acid ◽

Oxidative Stress Markers ◽

Acid Supplementation ◽

Stress Markers

Download Full-text

Effects of Alpha Lipoic Acid Supplementation on Serum Levels of Oxidative Stress, Inflammatory Markers and Clinical Prognosis among Acute Ischemic Stroke Patients: A Randomized, Double Blind, TNS Trial

Advanced Pharmaceutical Bulletin ◽

10.34172/apb.2020.034 ◽

2020 ◽

Vol 10 (2) ◽

pp. 284-289

Author(s):

Sheyda Shaafi ◽

Soraiya Ebrahimpour-Koujan ◽

Mohammad Khalili ◽

Seyad Morteza Shamshirgaran ◽

Mazyar Hashemilar ◽

...

Keyword(s):

Oxidative Stress ◽

Lipoic Acid ◽

Serum Levels ◽

Control Group ◽

Controlled Clinical Trial ◽

Alpha Lipoic Acid ◽

Randomized Controlled Clinical Trial ◽

Stroke Patients ◽

Randomized Controlled ◽

Tnf Α

Purpose: Stroke is one of the most common conditions causing death. There have been few studies examining the effects of alpha lipoic acid (ALA) on stroke patients. In this regard, the present randomized controlled clinical trial was conducted to examine the effects of ALA supplementation on serum albumin, and inflammatory and oxidative stress markers in stroke patients. Methods: The present paralleled randomized controlled clinical trial involved 42 stroke patients who were over 40 years and under enteral feeding. The participants were randomly assigned into two groups and finally 40 patients completed the study. Patients in alpha lipoic acid group (n=19) took 1200 mg ALA supplement daily along with their meal, and participants in control group (n=21) underwent the routine hospital diet for 3 weeks. Fasting blood samples were obtained and albumin, oxidative stress, and inflammatory indices were assessed at baseline, as well as at the end of the trial. Results: After 3 weeks, treatment of patients with ALA led to a significant decrease in tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) levels (P=0.01) compared to baseline. But serum levels of albumin, total antioxidant capacity (TAC), malondialdehyde (MDA), highsensitivity C-reactive protein (hs-CRP), IL-6 and TNF-α did not change significantly vs. control group (P>0.05). Conclusion: ALA did not significantly change the serum levels of albumin and inflammatory as well as antioxidant capacity indices in stroke patients compared with the control group. More clinical trials with large sample sizes and long duration are needed to clarify the effects of ALA on these patients.

Download Full-text